Abstracts tagged "Disease Activity"

Abstract Number: 3068 • 2016 ACR/ARHP Annual Meeting
Smoking and Excess Weight Attenuate Rate of Improvement over First 3 Years in Early RA
Susan J. Bartlett^1,2, Orit Schieir³, Kathleen Andersen⁴, Gilles Boire⁵, Boulos Haraoui⁶, Carol Hitchon⁷, Edward Keystone⁸, Janet E. Pope⁹, J Carter Thorne¹⁰, Diane Tin¹¹, Vivian P. Bykerk¹² and Canadian Early Arthritis Cohort (CATCH) Investigators, ¹Department of Medicine, Division of ClinEpi, Rheumatology, Respirology, McGill University, Montreal, QC, Canada, ²Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³University of Toronto, Toronto, ON, Canada, ⁴Rheumatology, Hospital for Special Surgery, New York, NY, ⁵Rheumatology Division, CHUS - Sherbrooke University, Sherbrooke, QC, Canada, ⁶1551, Ontario Street East, Institut de Recherche en Rhumatologie de Montréal (IRRM), Montreal, QC, Canada, ⁷University of Manitoba, Winnipeg, MB, Canada, ⁸Mt. Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁹University of Western Ontario, St Joseph's Health Care, London, ON, Canada, ¹⁰Southlake Regional Health Centre, Newmarket, ON, Canada, ¹¹The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, ¹²Divison of Rheumatology, Hospital for Special Surgery, New York, NY
Background/Purpose: Early, aggressive treatment to achieve remission is the primary goal when treating early RA, and is associated with improved long-term outcomes. We have previously…
Abstract Number: 31 • 2016 ACR/ARHP Annual Meeting
Patients with Either Rheumatoid Arthritis (RA) or Axial Spondyloarthritis (axSpA) Self-Reported Flares in 24% of Assessments: An Observational Study of 86 Patients Assessed Weekly over 3 Months (ie, 1,100 assessments)
Charlotte Jacquemin¹, Herve Servy², Anna Molto³, Jeremie Sellam⁴, Violaine Foltz¹, Frédérique Gandjbakhch¹, Christophe Hudry³, Stéphane Mitrovic¹, Bruno Fautrel¹ and Laure Gossec¹, ¹Rheumatology, Pitié Salpêtrière Hospital, Paris, France, ²Sanoia, La Ciotat, France, ³Rheumatology, Cochin Hospital, Paris, France, ⁴Rheumatology, Saint-Antoine Hospital, Paris, France
Background/Purpose: The evolution of RA and axSpA is characterized by alternated periods of flares and remission. This fluctuating disease activity can be self-assessed by a…
Abstract Number: 517 • 2016 ACR/ARHP Annual Meeting
Association of Rheumatoid Arthritis Disease Activity and Clinical Profile with Chronic Periodontitis
BEATRIZ RODRIGUEZ-LOZANO¹, Jorge Luis Garnier Rodríguez², Jerián González Febles³, Shashi Dadlani⁴, Ivan Ferraz-Amaro¹, Esmeralda Delgado Frías¹, Federico Díaz-González¹ and Mariano Sanz Alonso³, ¹Rheumatology, Hospital Universitario de Canarias, S/C Tenerife, Spain, ²Odontology, Dental Clinic Garnier, S/C Tenerife, Spain, ³Periodontology, Universidad Complutense de Madrid, Madrid, Spain, ⁴Periodontology, Dental Clinic Garnier, S/C Tenerife, Spain
Background/Purpose: Recent clinical data show a clear association between periodontitis (P) and RA. However, there is controversy over whether severity of P is associated with…
Abstract Number: 757 • 2016 ACR/ARHP Annual Meeting
Measures of Disease Activity in Patients with Persistently Active Systemic Lupus Erythematosus (SLE): Results from a Two-Part 52 Week Pilot Study of Repository Corticotropin Injection (H.P. Acthar® Gel)
Richard A. Furie¹, Margaret Mitrane², Enxu Zhao³ and Patrice Becker⁴, ¹Division of Rheumatology, North Shore LIJ Health System, Great Neck, NY, ²Manhattan BioPharm Consultants, New York, NY, ³Research and Development; Biometrics, Mallinckrodt Pharmaceuticals, Ellicott City, MD, ⁴Research & Development, Mallinckrodt Pharmaceuticals, Ellicott City, MD
Background/Purpose: Multiple outcome measures have been utilized in SLE clinical trials. Consistency of response assessed by different instruments enhances confidence in the efficacy of pharmacologic…
Abstract Number: 1220 • 2016 ACR/ARHP Annual Meeting
Comparison of Healthcare Utilization of Patients with Rheumatoid Arthritis Who Are Anti-Cyclic Citrullinated Peptide Antibody Positive Versus Negative
L Rosenblatt¹, K Price¹, Y Doleh¹, A Szymialis¹, M Eaddy², A Ogbonnaya², H-C Shih² and L Lamerato³, ¹Bristol-Myers Squibb, Princeton, NJ, ²Xcenda, LLC, Palm Harbor, FL, ³Henry Ford Health System, Detroit, MI
Background/Purpose: Anti-cyclic citrullinated peptide (CCP) antibody is a marker used in the diagnosis of RA, and it may be useful in identifying patients who are…
Abstract Number: 1484 • 2016 ACR/ARHP Annual Meeting
Exploring the Link Between RA Disease Activity, Lipid Levels, and Cardiovascular Disease in an Early Inflammatory Arthritis Cohort
Saurash Reddy, Xiaobo Meng and Carol Hitchon, University of Manitoba, Winnipeg, MB, Canada
Background/Purpose: Rheumatoid arthritis (RA) has been established as a risk factor for cardiovascular disease (CVD), with systemic inflammation being linked with atherosclerosis. Traditional CVD risk…
Abstract Number: 1702 • 2016 ACR/ARHP Annual Meeting
Baseline Patient Characteristics Associated with Response to Biologic Therapy in Patients with Psoriatic Arthritis Enrolled in the Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry
Philip J Mease¹, Chitra Karki², Mei Liu², Arthur Kavanaugh³, Christopher T. Ritchlin⁴, Doquyen H. Huynh³, Renganayaki Pandurengan², Jacqueline B. Palmer⁵ and Jeffrey D. Greenberg^2,6, ¹Swedish Medical Center and University of Washington, Seattle, WA, ²Corrona, LLC, Southborough, MA, ³University of California San Diego, La Jolla, CA, ⁴Allergy, Immunology and Rheumatololgy Division, University of Rochester Medical Center, Rochester, NY, ⁵Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁶New York University School of Medicine, New York, NY
Background/Purpose: The objective of this analysis was to investigate differences in baseline demographic and clinical characteristics of patients with psoriatic arthritis (PsA) who responded to…
Abstract Number: 2152 • 2016 ACR/ARHP Annual Meeting
S100A11 Protein Is Increased in Rheumatoid Arthritis and Is Associated with Disease Activity and Inflammation
Lucie Andres Cerezo¹, Barbora Šumová¹, Klára Prajzlerová¹, David Veigl², Karel Pavelka¹, Jiří Vencovský³ and Ladislav Senolt³, ¹Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic, ²1st Orthopaedic Clinic, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, ³Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic
Background/Purpose: Calgizzarin (S100A11) is a member of the S100 protein family that acts in different tumors via regulating number of biologic functions. Recent data suggest…
Abstract Number: 2539 • 2016 ACR/ARHP Annual Meeting
Analysis of Joints Susceptible to Rheumatoid Arthritis (RA) and Their Recovery Sequence Based on DAS28 and Physical Function Based on HAQ with Smart System of Disease Management (SSDM) in China：a Prospective Cohort Study
Rong Mu¹, Jing Yang², Hongzhi Wang³, Xinwang Duan⁴, Jianling Dong², Fengxiao Zhang⁵, Wenqiang Fan⁶, Huifang Guo⁷, Tong Xie⁸, Fei Xiao⁹, Hui Xiao⁹, Yuhua Jia⁹, Minjun Wang⁹, Yuan Liu⁹, Bing Wu⁹ and Zhanguo Li¹⁰, ¹Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China, ²Department of rheumatology, Central Hospital of MianYang, Sichuan, Mian Yang, China, ³The First Hospital of Jiaxing, Jiaxing, China, ⁴Department of rheumatology, The Second Affiliated Hospital of Nanchang University, Nanchang, China, ⁵Department of rheumatology, Hebei General Hospital, Shijiazhuang, China, ⁶Department of rheumatology, Central Hospital of XinXiang, Henan, XinXiang, China, ⁷The Second Hospital of Hebei Medical University, Shijiazhuang, China, ⁸Affiliated hospital of Guangdong medical University, Zhanjiang, China, ⁹Gothic Internet Technology Corporation, Shanghai, China, ¹⁰Peking University People's Hospital, Beijing, China
Background/Purpose: The disease activity score in 28 joints (DAS28) and health assessment questionnaire (HAQ) serve as guides for the treatment of rheumatoid arthritis (RA). Smart…
Abstract Number: 2811 • 2016 ACR/ARHP Annual Meeting
Predictors of Persistent Disease Activity and Persistent Remission in Systemic Lupus Erythematosus – Results from the Hopkins Lupus Cohort
Ioanna Giannakou¹, Katerina Chatzidionysiou², Noémi Györi³, Laurence S Magder⁴, Ronald F. van Vollenhoven^5,6 and Michelle Petri⁷, ¹Department of Medicine, Karolinska Institute, Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), Department of Medicine, Karolinska Institute, Stockholm, Sweden, ²Department of Medicine, Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), Department of Medicine, Karolinska Institute, Stockholm, Sweden, ³Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), Department of Medicine, Karolinska Institute, Stockholm, Sweden, ⁴Epidemiology and Public Health, Division of Rheumatology, School of Medicine, Johns Hopkins University, Baltimore, MD, ⁵Rheumatology Unit, Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), Department of Medicine, Karolinska Institute, Stockholm, Sweden, ⁶Amsterdam Rheumatology and Immunology Center (ARC), Amsterdam, Netherlands, ⁷Rheumatology Division, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Systemic lupus erythematosus (SLE) is characterized by a variability of disease expression, both between individuals and within individuals, over time. The aim of this…
Abstract Number: 3081 • 2016 ACR/ARHP Annual Meeting
Prognostic Factors of Death in a Cohort of 116 Adults with Hemophagocytic Syndrome: Impact of Underlying Disease and Laboratory Parameters
Pilar Brito-Zerón¹, Pedro Moral Moral², Belchin Kostov³, Luis Caminal-Montero⁴, Guadalupe Fraile⁵, Eva Fonseca⁶, Patricia Pérez Guerrero⁷, Angel Robles⁸, Antonio J. Chamorro⁹, María Andrés Calvo¹⁰, José Ramón Larrañaga¹¹, Maria José Forner¹², Mónica Rodriguez Carballeira¹³, Manuel Ruiz Muñoz¹⁴, Roberto Hurtado García¹⁵, Luis Fernando Viejo Llorente¹⁶, Sergio Prieto-González¹⁷, Pedro Castro¹⁸, Aleida Martínez Zapico⁴, María Vaquero Herrero⁹, Angela Ruiz de Temiño de la Peña¹⁰, Soledad Retamozo^1,19, Manuel Ramos-Casals²⁰ and REGHEM-GEAS-SEMI Spanish Cohort, ¹Laboratory of Systemic Autoimmune Diseases “Josep Font”, CELLEX, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Department of Systemic Autoimmune Diseases, ICMID, Hospital Clinic, Barcelona, Barcelona, Spain, ²Department of Internal Medicine, Hospital La Fé, Valencia, Valencia, Spain, ³Research Group in Primary Care, IDIBAPS, ABS Les Corts, CAPSE, Barcelona, Spain, ⁴Department of Internal Medicine, Hospital Universitario Central de Asturias, Oviedo, Spain, ⁵Department of Internal Medicine, Hospital Ramón y Cajal, Madrid, Spain, Madrid, Spain, ⁶Department of Internal Medicine, Hospital de Cabueñes, Gijón, Gijón, Spain, ⁷Department of Internal Medicine, Hospital Universitario Puerta del Mar, Cádiz, Cadiz, Spain, ⁸Department of Internal Medicine, Hospital La Paz, Madrid, Madrid, Spain, ⁹Department of Internal Medicine, Complejo Asistencial Universitario de Salamanca, Salamanca, Spain, ¹⁰Department of Internal Medicine, Hospital Rio Hortega, Valladolid, Valladolid, Spain, ¹¹Department of Internal Medicine, Hospital Xeral, Vigo, Vigo, Spain, ¹²Department of Internal Medicine, Hospital Clínico de Valencia, Valencia, Spain, ¹³Department of Internal Medicine, Hospital Mutua de Terrasa, Terrasa, Spain, ¹⁴Department of Internal Medicine, Hospital Universitario Fundacion Alcorcón, Madrid, Spain, ¹⁵Department of Internal Medicine, Hospital Vega Baja, Orihuela, Orihuela, Spain, ¹⁶Department of Internal Medicine, Hospital Virgen de la Salud, Toledo, Toledo, Spain, ¹⁷Department of Autoimmune Diseases, ICMiD, Hospital Clínic, Barcelona, Barcelona, Spain, ¹⁸Medical Intensive Care Unit, ICMiD, Hospital Clínic, Barcelona, Barcelona, Spain, ¹⁹Rheumatology Unit, Hospital Privado Centro Médico de Córdoba, Argentina, Córdoba, Argentina, ²⁰Laboratory of Systemic Autoimmune Diseases “Josep Font”, CELLEX, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Department of Systemic Autoimmune Diseases, ICMID, Hospital Clinic, Barcelona, Spain, Barcelona, Spain
Background/Purpose: To analyze the potential use of the main features at diagnosis (epidemiological, clinical, laboratory) as prognostic factors and to estimate the risk of death…
Abstract Number: 86 • 2016 ACR/ARHP Annual Meeting
Optimizing the Efficiency of Patient Data Capture Using Smartphone Technology: Evaluation of the Correlation Between Promis Instruments for PRO Data Capture
Huifeng Yun¹, Jennifer Beaumont², Shuo Yang³, James Willig⁴, W. Ben Nowell⁵, Seth D. Ginsberg⁶, Kelly V. Clayton⁷, Shantana Hazel^7,8, Carole Wiedmeyer⁵ and Jeffrey Curtis⁹, ¹Epidemiology, University of Alabama at Birmingham School of Public Health, Birmingham, AL, ²Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL, ³Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁴Med - Infectious Diseases, University of Alabama at Birmingham, Birmingham, AL, ⁵CreakyJoints/Global Health Living Foundation, Upper Nyack, NY, ⁶Global Healthy Living Foundation, CreakyJoints, Upper Nyack, NY, ⁷Global Healthy Living Foundation, Upper Nyack, NY, ⁸Sister Girl Foundation, Inc., Upper Nyack, NY, ⁹Division Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Patient-reported outcomes (PROs) are key to enabling the comprehensive assessment of patient-centered benefits in comparative effectiveness research (CER). However, the relationships between different PROMIS…
Abstract Number: 519 • 2016 ACR/ARHP Annual Meeting
Greater Fatigue at Baseline and Female Gender Predict Worse Disability in Early RA Despite Treatment to Target: A Comparison of Two Observational Cohort Studies from the United Kingdom
Sarah Twigg¹, Elizabeth M.A. Hensor², Jane E. Freeston¹, Ai Lyn Tan¹, Alan Tennant³, Paul Emery⁴, Ann Morgan⁵ and YEAR consortium, IACON consortium , ¹NIHR Leeds Musculoskeletal Biomedical Research Unit, University of Leeds, Leeds, United Kingdom, ²NIHR-Leeds Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom, ³Swiss Paraplegic Research,, Nottwil, Switzerland, ⁴NIHR Leeds Musculoskeletal Biomedical Research Unit and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, University of Leeds, Leeds, United Kingdom, ⁵NIHR-Leeds Musculoskeletal Biomedical Research Unit, University of Leeds, Leeds, United Kingdom
Background/Purpose: Although disability is part of the ‘core set’ of outcomes for RA research recommended by OMERACT (1), current therapeutic strategies focus on inflammation. The…
Abstract Number: 772 • 2016 ACR/ARHP Annual Meeting
Effect of HMG-CoA Reductase Inhibitor Drugs (Statins) on Systemic Lupus Erythematosus Disease Activity: A Systematic Review and Meta-Analysis
Givenchy Maree Garcia, Annalyn Urbano and Evelyn Salido, Section of Rheumatology, University of the Philippines - Philippine General Hospital, Manila, Philippines
Background/Purpose: Statins have been shown to have anti-inflammatory and immunomodulatory effects. In vitro studies show that these drugs inhibit inflammatory cells, decrease the expression of…
Abstract Number: 1226 • 2016 ACR/ARHP Annual Meeting
Evaluation of the Association Between C-Reactive Protein and Anti-Citrullinated Protein Antibody in Rheumatoid Arthritis: Analysis of Two Clinical Practice Data Sets
E Alemao¹, Z Guo¹, L Burns¹, M Frits², Jonathan Coblyn², Michael Weinblatt² and NA Shadick², ¹Bristol-Myers Squibb, Princeton, NJ, ²Brigham and Women’s Hospital, Boston, MA
Background/Purpose: The association between inflammatory markers such as CRP or ESR and joint damage has been widely established in RA. Autoantibodies such as RF and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.